

## Board of Directors Meeting in Public - Cover Sheet

<b>Subject:</b>	<b>Research and Development Quarterly Update</b>	<b>Date: 14<sup>th</sup> November 2018</b>		
<b>Prepared By:</b>	Alison Steel, Research and Innovation Manager			
<b>Approved By:</b>	David Hodgson, Research and Innovation Director			
<b>Presented By:</b>	Alison Steel, Research and Innovation Manager			
<b>Purpose</b>				
Summary of R&I metrics and benchmarking performance (Q2) Assurance of financial position at Q2  Workforce update  R&I collaborations  Outline of 2018-2019 Strategic priorities			<b>Decision</b>	
			<b>Approval</b>	
			<b>Assurance</b>	X
			<b>Consider</b>	
<b>Strategic Objectives</b>				
<b>To provide outstanding care to our patients</b>	<b>To support each other to do a great job</b>	<b>To inspire excellence</b>	<b>To get the most from our resources</b>	<b>To play a leading role in transforming health and care services</b>
X		X	X	X
<b>Overall Level of Assurance</b>				
	<b>Significant</b>	<b>Sufficient</b>	<b>Limited</b>	<b>None</b>
		X		
<b>Risks/Issues</b>				
<b>Financial</b>	<ul style="list-style-type: none"> <li>Risk of further reduction in EMCRN budget 2019/20 despite high performance</li> <li>Work ongoing with Estates and Facilities to identify Clinical Research Facility space. If delayed long term this will impede growth of the commercial research portfolio</li> <li>Inability to build research capacity and capability over the next several years and develop the R&amp;I business model if income generated from commercial trials is not directly used towards supporting R&amp;I growth</li> </ul>			
<b>Patient Impact</b>	Decreased opportunity for our patient population to take part in research and access new and novel treatments, and increase quality of patient care at SFH			
<b>Staff Impact</b>	Creative use of funding in developing new research secondments and working together with Senior nurse leaders to develop Nurse Research Academy			
<b>Services</b>				
<b>Reputational</b>	Currently have a strong reputation for research delivery across the region and have been praised for strengths in financial probity, overall recruitment and recruitment to time and target by the EMCRN. Risk this may be affected if research portfolio and complexity remains static			
<b>Committees/groups where this item has been presented before</b>				
Clinical Audit and Effectiveness Group – 27 <sup>th</sup> September – different format				
<b>Executive Summary</b>				
Recruitment performance in Research and Innovation at SFH continues to increase. Q2 performance 2018/19:				

## Board of Directors Meeting in Public - Cover Sheet

1. 1216 participants recruited in 18/19 c.f to 858 in 17/18, 42% increase
2. 87% of annual target achieved
3. 74 studies are open at SFH with 61 actively recruiting
4. 82% of commercial and 66% of non-commercial studies are recruiting to 100% time and target
5. Trials are spread across most specialities in the organisation with more clinical research activity being conducted in the areas of Cancer, Cardiovascular disease, Gastroenterology, Reproductive Health and Childbirth and Stroke. New areas opening studies e.g Audiology
6. Charts 1-4 provide visual performance data
7. Chart 5 provides complexity weighting for 18/19 recruitment

Research activity in the organisation is increasing year on year, giving more patients the opportunity to participate in studies allowing them access to novel treatments and interventions.

Commercial pharmaceutical and medical device research is also growing at SFH creating an excellent reputation for delivery with commercial sponsors, subsequently attracting new and renewed business. SFH is now being supported as a priority growth area by East Midlands Clinical Research Network. Progress against plan is detailed.

Final budget for 2018/19 of £714,137.55 is based on a 2.3% reduction. 2019/2020 budget is based on performance of previous 2 financial years which has been high.

Patient experience survey re-launched, 34 patients surveyed, overall 99.45% satisfaction. Detailed reporting planned for end of year

### 2018/19 Strategic Aims:

1. Strong research activity in more clinical specialities, define and secure our areas of strength and establish high class research facilities
2. Work with more industry organisations to deliver clinical trials that change people's lives for the better
3. Involve more of our patients and staff in high quality research
4. Develop and support a workforce with the skills to deliver world class research

The service we provide continues to deliver better outcomes for patients, allowing them access to new and different treatments. The reputation of the Research and Innovation department and SFH as a research active organisation continues to grow. We have strong associations with other NHS Trusts and Universities and are committed to expanding the research activity, breadth of our portfolio and facilities at SFH through delivering our research strategy.

Studies show at a local level research can have positive outcomes in terms of increased quality of care, patient satisfaction and financial benefits to the organisation. It is well known that organisations that are research active provide better care to their patients and have better outcomes. It is important as a research active organisation that wherever possible we continue to make the changes and meet the requirements needed to advance our research activity and build research capacity for the future.